Arsenal Biosciences, commonly known as ArsenalBio, has achieved a remarkable milestone by securing $325 million in a Series C funding round. This significant financial boost arrives amid a challenging year for biotech investments, particularly in the cell and gene therapy sectors. The raised
Sanofi, a leading pharmaceutical company, recently announced the results of its clinical trials for tolebrutinib, an experimental drug targeting multiple sclerosis (MS). The mixed outcomes have generated a buzz within the medical and investment communities. While the drug did not outperform an
Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and
In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These milestones highlight
The biopharmaceutical excipients market has been witnessing rapid advancements, paving the way for significant evolution by 2029. These excipients, which are vital components of drug formulations, play crucial roles in enhancing drug efficacy, stability, and delivery. As the market grows, driven by
Pfizer Inc. has unveiled a significant advancement in their ongoing Phase 3 MONeT trial, specifically through a substudy aiming to evaluate the efficacy and safety of its RSV vaccine, ABRYSVO, in immunocompromised adults. Historically, this vulnerable population has faced severe complications from
Grail, a leading player in the cancer detection industry, is making a significant cut to its workforce, laying off approximately 350 employees, which represents about 25% of its total workforce. This substantial reduction is part of a major restructuring effort aimed at refocusing the company’s
Cybersecurity in the pharmaceutical industry has never been more imperative. The urgency of protecting sensitive data, ranging from proprietary research to personal patient details, is heightened by the increasing sophistication of cyber threats. With the advent of the COVID-19 pandemic,
The U.S. Food and Drug Administration (FDA) has ushered in a new era in cancer treatment with the approval of Tecelra (afamitresgene autoleucel), an innovative therapy aimed at combating synovial sarcoma. This rare and aggressive form of cancer predominantly impacts young adults and has
US Specialty Formulations (USSF) has announced an ambitious $15 million expansion of its biopharma facility in Allentown, Pennsylvania. This initiative, highlighted in a July 31, 2024 press release, is aimed at significantly boosting the company's production capabilities and economic impact on the
